insights_auto
Why is 688235 up 4.06%?
Dive Deeperchevron_right
688235:SHA
BeOne Medicines AG
CN¥255.98
arrow_upward
+4.06%(+9.99) 1D
Oct 16, 3:00:00 PM GMT+8 · CNY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 688235...
Open
CN¥253.20
High
CN¥268.18
Low
CN¥252.09
Mkt. cap
303.26B
Avg. vol.
2.81M
Volume
5.69M
P/E ratio
91.43
52-wk high
CN¥319.24
52-wk low
CN¥205.51
EPS
CN¥2.80
No. of employees
12K
Open
CN¥253.20
High
CN¥268.18
Low
CN¥252.09
Mkt. cap
303.26B
Avg. vol.
2.81M
Volume
5.69M
P/E ratio
91.43
52-wk high
CN¥319.24
52-wk low
CN¥205.51
EPS
CN¥2.80
No. of employees
12K
News stories
From web sources and news partners
ad-hoc-news.de
·
3 hours ago
Morgan Stanley lifts target for BeOne Medicines stock to USD 425.00
Simply Wall Street
·
17 hours ago
Is BeOne Medicines (ONC) Undervalued As Earnings Estimates Jump?
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12K
FoundedOct 28, 2010
Headquarters-
SectorBiotechnology
Websitebeonemedicines.com